Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IM CannabisIMCC -10.26%37 3-Year EPS without NRI Growth Rate is 36.20% as of Jun. 2026, which is 84% above its 10-year median of 19.70. GuruFocus rates IMCC with a GF Score™ of 37/100 and a GF Value™ of $23.46 (Possible Value Trap). The stock has 8 warning signs investors should review. Among 786 Drug Manufacturers companies, IM Cannabis ranks better than 80.92% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 36.20% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 29.20% per year.
During the past 10 years, the average EPS without NRI Growth Rate was -6.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of IM Cannabis was 89.60% per year. The lowest was -351.10% per year. And the median was 19.70% per year.
IM Cannabis (NAS:IMCC) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
IM Cannabis 3-Year EPS without NRI Growth Rate Related Terms
IMCC vs SHPH, PLSH, AKAN: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, IM Cannabis's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IM Cannabis 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, IM Cannabis's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where IM Cannabis's 3-Year EPS without NRI Growth Rate falls into.
IM Cannabis 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 36.20% mean?
IM Cannabis (IMCC) has a 3-Year EPS without NRI Growth Rate of 36.20% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for IM Cannabis and its competitors. This is 84% above median its historical median of 19.70. According to the industry distribution chart, IM Cannabis ranks #150 out of 786 companies in the Drug Manufacturers industry, placing it in the top 19.1%.
Is IM Cannabis' 3-Year EPS without NRI Growth Rate too high?
IM Cannabis' current 3-Year EPS without NRI Growth Rate of 36.20% is 84% above median its 10-year median of 19.70. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.85. IM Cannabis' value of 36.20% is 267.5% above this industry median. Based on the distribution chart, IM Cannabis ranks #150 out of 786 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, IM Cannabis has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does IM Cannabis' 3-Year EPS without NRI Growth Rate compare to SHPH and PLSH?
According to the Drug Manufacturers industry distribution chart, IM Cannabis ranks #150 out of 786 companies for 3-Year EPS without NRI Growth Rate. This places IM Cannabis in the top 19% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 9.85. IM Cannabis' value of 36.20% is 267.5% above this benchmark. While the company's 10-year median is 19.70 vs. the industry median of 9.85, IM Cannabis has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.85, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IM Cannabis's current 3-Year EPS without NRI Growth Rate of 36.20% is 267.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for IM Cannabis and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IM Cannabis's current 3-Year EPS without NRI Growth Rate is 36.20%, which is 84% above median its own 10-year median of 19.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IM Cannabis stock overvalued right now?
Based on GuruFocus' analysis, IM Cannabis (IMCC) is currently considered Possible Value Trap. The stock's GF Value™ is $23.46, compared to a current price of $3.03 — trading 87.1% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 36.20%, which is 84% above median its 10-year median of 19.70 and 267.5% above the Drug Manufacturers industry median of 9.85. IM Cannabis' overall GF Score™ is 37/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For IM Cannabis (IMCC), the current 3-Year EPS without NRI Growth Rate is 36.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IM Cannabis (IMCC) Overvalued in 2026?
Based on GuruFocus' analysis, IM Cannabis stock appears to be undervalued.
The current stock price of $3.03 is trading 87.1% below its estimated GF Value™ of $23.46.
GuruFocus considers IM Cannabis to be Possible Value Trap.
Key valuation signals for IMCC:
3-Year EPS without NRI Growth Rate: 36.20% (84% above median its 10-year median of 19.70)
GF Value™: $23.46 vs. price of $3.03 (87.1% below fair value)
Industry Position: 267.5% above the Drug Manufacturers median (#150 of 786)
No single metric tells the full story. See the IMCC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority revenue is generated from Germany, and also has its presence in Israel.
37GF Score
Get the complete analysis for IMCC
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMCC has been successfully added to your 
